Research progress in clinical application of lymphoplasmapheresis in immune-related diseases
10.13303/j.cjbt.issn.1004-549x.2022.08.026
- VernacularTitle:淋巴血浆置换术在免疫相关性疾病中的临床应用
- Author:
Shipeng KE
1
;
Xu LI
2
;
Ling YU
3
;
Ting HUANG
3
;
Huixia ZHANG
3
;
Fen HU
3
;
Shubiao ZOU
3
;
Meiying RAO
3
;
Simei CHEN
3
Author Information
1. Second Clinical School of Medicine, Nanchang University, Nanchang 330006, China
2. School of Public Health Administration, Nanchang University, Nanchang 330006, China
3. Department of Blood Transfusion, Second Affiliated Hospital, Nanchang University, Nanchang 330006, China
- Publication Type:Journal Article
- Keywords:
lymphoplasmapheresis;
autoimmune disease;
guillain-barré syndrome;
rheumatoid arthritis;
myasthenia gravis
- From:
Chinese Journal of Blood Transfusion
2022;35(8):882-886
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoplasmapheresis(LPE) is a combination of plasma exchange and lymphocyte separation technology. It can not only remove autoimmune antibodies, but also remove the immune active cells producing these antibodies. At the same time, it can inhibit cellular and humoral immune responses, and improve the efficiency and reliability of treatment. This technology is safe, reliable, and easy to operate. In recent years, it has been widely used in the treatment of various autoimmune diseases and the suppression of immune rejection after organ transplantation, especially in the treatment of critically ill patients. This paper summarizes the clinical application status of LPE in immune-related diseases at home and abroad, analyzes the problems existing in the clinical promotion of LPE, and makes a prospect of its application value.
